Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sanofi (SNYNF – Research Report) and Personalis (PSNL – Research Report).
Sanofi (SNYNF)
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on Sanofi today and set a price target of EUR85.00. The company’s shares closed last Friday at $92.88.
According to TipRanks.com, Papadakis is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sanofi with a $114.97 average price target, a 23.8% upside from current levels. In a report issued on January 25, Barclays also maintained a Hold rating on the stock with a EUR90.00 price target.
See today’s best-performing stocks on TipRanks >>
Personalis (PSNL)
Personalis received a Buy rating and an $8.00 price target from Needham analyst Michael Matson today. The company’s shares closed last Friday at $3.90.
According to TipRanks.com, Matson is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Personalis with a $9.67 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNYNF:
- Sanofi sees 2023 business EPS up at low single digit rate at CER
- Sanofi reports Q4 business EPS EUR 1.71, up 17.4% at CER
- Sanofi price target raised to EUR 100 from EUR 91 at Berenberg
- Sanofi plans to lay off staff at vaccine factories in India, Reuters says
- Regeneron, Sanofi announce EC expansion of Dupixent marketing authorization
